Zydus secures U.S. FDA nod for scurvy injection generic

Zydus has received approval from the US Food and Drug Administration (FDA) for a generic version of a scurvy injection. This approval allows Zydus to manufacture and market the product in the US, which will be made at its plant in Jarod, near Vadodara. The approval is significant for Zydus as it expands the company's presence in the US market, where it can now offer a generic alternative to a branded product, potentially increasing its market share and revenue.

Why it matters

Zydus has received US FDA approval for a generic scurvy injection. This could increase the company's revenue and market share in the US.

Market impact

Markets & countries in focus

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to The Hindu. For information only — not financial advice.